{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T06:39:24.782017+00:00","company":{"ticker":"AXSM","cik":1579428,"company_name":"Axsome Therapeutics, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"2d9524a1b14487391651028d70a5148d2b7e7ab6","cik":1579428,"ticker":"AXSM","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","payload":{"eps_text":"$(1.26) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$(64.5) million","period_text":"first quarter of 2026","report_date":"2026-05-04","result_type":"reported_results","revenue_text":"$191.2 million"},"claim":"Axsome Therapeutics, Inc. reported first quarter of 2026 results: revenue $191.2 million, net income $(64.5) million, EPS $(1.26) per share.","evidence_excerpt":"Total net product revenue was $191.2 million for the first quarter of 2026, representing 57% year-over-year growth.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-202506","anchor_url":"https://secwatch.observer/filing/0001193125-26-202506#claim-2d9524a1b14487391651028d70a5148d2b7e7ab6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/0001193125-26-202506-index.htm"},{"fact_type":"earnings_release","fact_key":"6ee411e5a2f1d315b432497964cc3289fb708db4","cik":1579428,"ticker":"AXSM","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-05-06T23:59:59+00:00","payload":{"eps_text":"$(1.44) per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$68.4 million","period_text":"first quarter of 2024","report_date":"2024-05-06","result_type":"reported_results","revenue_text":"$75.0 million"},"claim":"Axsome Therapeutics, Inc. reported first quarter of 2024 results: revenue $75.0 million, net income $68.4 million, EPS $(1.44) per share.","evidence_excerpt":"Total net product revenue for the first quarter of 2024 was $75.0 million, representing 160% year-over-year growth.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-053197","anchor_url":"https://secwatch.observer/filing/0000950170-24-053197#claim-6ee411e5a2f1d315b432497964cc3289fb708db4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024053197/0000950170-24-053197-index.htm"}]}